Kassim Rahawi, PharmD, Sanofi, Cambridge, USA

home / authors / kassim-rahawi-sanofi-cambridge-usa

Articles

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

April W. Armstrong, MD, MPH, Professor and Chief of Dermatology​, University of California, Los Angeles​;Kassim Rahawi, PharmD, Sanofi, Cambridge, USA;Wendell Valdecantos, MD, Sanofi, Cambridge, USA;Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA
October 22nd 2024

Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
POLL: Which Cosmeceuticals Are Most Popular, According to Social Media?
Published: April 10th 2025 | Updated: May 2nd 2025
POLL: Which Cosmeceuticals Are Most Popular, According to Social Media?
Shawn Kwatra, MD, Endowed as Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine
Published: April 16th 2025 | Updated: May 2nd 2025
Shawn Kwatra, MD, Endowed as Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine
SLIDESHOW: 2025 Pre-AAD Meetings
Published: March 4th 2025 | Updated: May 2nd 2025
SLIDESHOW: 2025 Pre-AAD Meetings
Addressing the Challenges of Pigmentary Disorders in Women Across the Fitzpatrick Skin Spectrum
Published: March 19th 2025 | Updated: May 2nd 2025
Addressing the Challenges of Pigmentary Disorders in Women Across the Fitzpatrick Skin Spectrum
FDA Approves First Gene Therapy for RDEB
Published: April 29th 2025 | Updated: May 2nd 2025
FDA Approves First Gene Therapy for RDEB
© 2025 MJH Life Sciences

All rights reserved.